JP4465728B2 - Dragees - Google Patents
Dragees Download PDFInfo
- Publication number
- JP4465728B2 JP4465728B2 JP35061998A JP35061998A JP4465728B2 JP 4465728 B2 JP4465728 B2 JP 4465728B2 JP 35061998 A JP35061998 A JP 35061998A JP 35061998 A JP35061998 A JP 35061998A JP 4465728 B2 JP4465728 B2 JP 4465728B2
- Authority
- JP
- Japan
- Prior art keywords
- tablet
- sugar
- coating
- water
- sucrose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は糖衣錠の保護皮膜に関する。さらに詳しくは、保護皮膜の溶解性を改善して糖衣錠の崩壊時間を短縮する技術に関する。
【0002】
【従来の技術】
糖衣錠は、美観を呈する、甘くて飲みやすい、酸素や水分の透過が少ないなどの利点を有するものの、フィルムコート錠などに比べて崩壊時間が長いという欠点を有しており、そのため、速効性を求められる薬物、例えば、解熱鎮痛成分などを含有する場合には、糖衣錠という剤型は採択し難いという事情があった。
【0003】
このような欠点を解消するため、糖衣皮膜を薄くしたり、あるいは、通常、糖衣皮膜に先だって施されるところの保護皮膜を施さず、内核錠に直接糖衣液を塗布することも可能ではある。
【0004】
しかしながら、糖衣皮膜を薄くすると糖衣錠の強度が弱くなり、また、内核錠に直接糖衣液を塗布すると、内核錠への水分の浸透、内核錠中の成分の糖衣層への染み出し、内核錠の膨潤による糖衣層のひび割れなどの弊害が生じ、したがって、これらは崩壊時間の短縮措置としては必ずしも充分なものとは言えなかった。
【0005】
【発明が解決しようとする課題】
本発明は、糖衣錠の強度を確保し、内核錠への水分の浸透などを防止しつつ、崩壊時間の短縮された糖衣錠を提供することを課題とする。
【0006】
【課題を解決するための手段】
本発明者らは、糖衣錠の崩壊時間を短縮するために鋭意検討を重ねてきた。糖衣錠には、内核錠の安定性などの観点から、一般的に、水溶性高分子からなる保護皮膜が施される。しかし、検討の過程で、糖衣錠の崩壊時間には保護皮膜の溶解速度が大きく影響していること、すなわち、ヒドロキシプロピルメチルセルロースなどの水溶性高分子を保護皮膜として用いた場合、速やかに溶解する糖衣皮膜に比して保護皮膜の溶解速度が律速となって、糖衣錠の崩壊時間が遅延することを見出した。
【0007】
そこで、本発明者らは、保護皮膜の溶解時間を短縮するために更に検討したところ、水溶性高分子の溶解液にショ糖のような水溶性糖類を含有させて保護皮膜を形成させると、保護皮膜本来の作用を損なうことなく、その水溶解性を高めることができ、糖衣錠の崩壊促進に繋がることを見出した。
【0008】
かかる知見に基づき完成した本発明は、内核錠に直接施された保護皮膜が、水溶性高分子および水溶性糖類からなることを特徴とする糖衣錠である。
【0009】
【発明の実施の形態】
保護皮膜とは、内核錠と糖衣皮膜の間にあって、内核錠に直接施されている皮膜である。一般に、ヒドロキシプロピルメチルセルロースなどの水溶性高分子が用いられている。その作用は、コーティング中に糖衣液が直接内核錠にかかり錠剤内部に水分が浸透するのを防止し、コーティング後は内核錠中の成分が糖衣層へ染み出したり、内核錠が膨潤して糖衣層にひび割れが生じたりするのを防止することである。通常、この保護皮膜を施さない場合には、水分の浸透や内核錠成分の染みだし、ひび割れが生じ易くなる。
【0010】
ここに、内核錠とは、主薬成分を含有する被覆される前の錠剤であって、素錠、裸錠などともいう。
【0011】
本発明の水溶性高分子は、吸湿性が低く、膨潤性の小さいものが望ましく、このような性質を有する水溶性高分子としてはヒドロキシプロピルメチルセルロース、ヒドロキシプロピルセルロースが該当する。これらは単独で配合してもよく、また、2種以上を組み合わせて配合してもよい。
【0012】
本発明の水溶性糖類は、25℃の水に対する溶解度が0.3〜3g/gである糖類が好ましく、このような糖類としては、例えば、マルチト−ル、エリスリト−ル、ブドウ糖、ショ糖などが挙げられる。ただし、コーティング中の錠剤への水分の浸透を勘案すれば、コーティング液中の水分量は少ない方が望ましいので、水に対する溶解度が大きく、少量の水でも多量に溶解させることができるショ糖が特に好ましい。
水溶性高分子と水溶性糖類の重量比は1:0.1〜1:3であり、保護皮膜としてのフィルム強度を維持するという点からは、1:0.5〜1:1.5が好ましい。
水溶性高分子および水溶性糖類からなる保護皮膜の被覆量は、内核錠の処方にもよるが、通常、内核錠の重量に対し1〜15重量%であり、内核錠の膨潤による糖衣錠のひび割れ防止するという点からは、2〜10重量%が好ましい。
【0013】
本発明の糖衣錠は、水溶性高分子および水溶性糖類からなる保護皮膜を内核錠に施す他は、通常のコーティング方法により中掛け層、上掛け層を形成させることにより調製することができる。
【0014】
【発明の効果】
本発明により、崩壊時間が短縮された糖衣錠を提供することが可能となった。
【0015】
【実施例】
以下、実施例、比較例および試験例により本発明をさらに詳細に説明する。
【0016】
(実施例1)
[内核錠の製造]
乳糖 2700g
ヒドロキシプロピルセルロース 340g
コーンスターチ 1100g
結晶セルロース 340g
低置換度ヒドロキシプロピルセルロース 200g
軽質無水ケイ酸 40g
ステアリン酸マグネシウム 20g
上記成分を混合して得られた粉体を打錠し、錠径9mm、1錠重量235mgの錠剤を得た。これを内核錠とした。
【0017】
[保護皮膜液の製造]
精製水900gにヒドロキシプロピルメチルセルロース50gを撹拌溶解させた後、ショ糖50gを加えて40℃で加温溶解させて保護皮膜液を得た。
【0018】
[保護皮膜層の製造]
コーティング装置に内核錠を入れ、保護皮膜液をスプレーコーティングし、1錠当たり約20mgまで保護皮膜層を施した。
【0019】
[中掛け層の製造]
プルラン 24g
メトローズSB−4(信越化学製) 12g
バレイショデンプン 24g
プルロニックF68(旭電化製) 10.8g
ショ糖 1084.6g
軽質無水ケイ酸 10.8g
カルメロースカルシウム 24g
タルク 208g
炭酸カルシウム 208g
上記成分を精製水535gに懸濁、加温溶解させてコーティング液を調製した。保護皮膜層を施した錠剤に対し、コーティング液を1錠当たり約80mgまで塗布して中掛け層を形成させた。
【0020】
[上掛け層の製造]
ショ糖1000gを精製水490gに加温溶解させてコーティング液を調製した。中掛け層まで施した錠剤に対し、コーティング液を1錠当たり約50mgまで塗布して上掛け層を形成させた。最後にカルナバワックスで艶出しを行って、1錠重量約385mgの糖衣錠を得た。
(比較例1)
[保護皮膜液の製造]
精製水900gにヒドロキシプロピルメチルセルロース100gを撹拌溶解させて保護皮膜液を得た。
【0021】
[保護皮膜層の製造]
コーティング装置に実施例1で得られたた内核錠を入れ、保護皮膜液をスプレーコーティングし、1錠当たり約20mgまで保護皮膜層を施した。
【0022】
[中掛け層、上掛け層の製造]
中掛け層、上掛け層および艶出しは実施例1と同様の処方で行い、1錠重量約385mgの糖衣錠を得た。
【0023】
(実施例2)
[内核錠の製造]
イブプロフェン 1125g
ヒドロキシプロピルセルロース 300g
低置換度ヒドロキシプロピルセルロース 1425g
結晶セルロース 1500g
上記成分を混合して得られた粉体を精製水を造粒溶媒として攪拌造粒し、乾燥後、ステマグ21gを添加して混合した。得られた顆粒を打錠し、錠径9mm、1錠重量250mgの錠剤を得た。これを内核錠とした。
【0024】
[保護皮膜液の製造]
精製水900gにヒドロキシプロピルメチルセルロース50gを撹拌溶解させた後、ショ糖50gを加えて40℃で加温溶解させて保護皮膜液を得た。
【0025】
[保護皮膜層の製造]
コーティング装置に実施例1で得られた内核錠を入れ、保護皮膜液をスプレーコーティングし、1錠当たり約20mgまで保護皮膜層を施した。
【0026】
[中掛け層、上掛け層の製造]
ショ糖800g、プルラン17gを精製水570gに加温溶解させてコーティング液を調製した。保護皮膜層を施した錠剤に対し、コーティング液を1錠当たり約85mgまで塗布して、糖衣層を形成させた。最後にカルナバワックスで艶出しを行って、1錠重量約355mgの糖衣錠を得た。
(試験例)
実施例1および比較例1で得られた糖衣錠各々6錠について、試験液として37℃の精製水を用いて第13改正日本薬局方に準じて崩壊試験を行った。その結果を表1に示す。
【0027】
【表1】
【0028】
表1により、ヒドロキシプロピルメチルセルロースとショ糖からなる保護皮膜を施した場合(実施例1)は、ヒドロキシプロピルセルロースのみからなる保護皮膜を施した場合(比較例1)に比べて崩壊時間をおよそ3割短縮できることが判った。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a protective coating for sugar-coated tablets. More specifically, the present invention relates to a technique for improving the solubility of a protective film and shortening the disintegration time of a sugar-coated tablet.
[0002]
[Prior art]
Although sugar-coated tablets have the advantages of being aesthetically pleasing, sweet and easy to drink, and having less oxygen and moisture permeation, they have the disadvantage of a longer disintegration time than film-coated tablets. In the case of containing a required drug, for example, an antipyretic analgesic component, a dosage form called sugar-coated tablet is difficult to adopt.
[0003]
In order to eliminate such drawbacks, it is possible to make the sugar coating thin or to apply the sugar coating directly to the inner core tablet without applying the protective coating which is usually applied prior to the sugar coating.
[0004]
However, when the sugar coating is thinned, the strength of the sugar-coated tablet is weakened. Defects such as cracking of the sugar-coating layer due to swelling occurred, and therefore, these were not necessarily sufficient as measures for shortening the disintegration time.
[0005]
[Problems to be solved by the invention]
An object of the present invention is to provide a sugar-coated tablet with a shortened disintegration time while ensuring the strength of the sugar-coated tablet and preventing moisture penetration into the inner core tablet.
[0006]
[Means for Solving the Problems]
The present inventors have intensively studied to shorten the disintegration time of the sugar-coated tablets. In general, sugar-coated tablets are provided with a protective film made of a water-soluble polymer from the viewpoint of the stability of the core tablet. However, in the course of the study, the dissolution rate of the protective coating greatly affects the disintegration time of the sugar-coated tablets, that is, when a water-soluble polymer such as hydroxypropylmethylcellulose is used as the protective coating, It was found that the dissolution rate of the protective coating was rate-limiting compared to the coating, and the disintegration time of the sugar-coated tablets was delayed.
[0007]
Therefore, the present inventors further studied to shorten the dissolution time of the protective film, and when a water-soluble saccharide such as sucrose is contained in the water-soluble polymer solution to form a protective film, It has been found that its water solubility can be increased without impairing the original function of the protective film, leading to the accelerated disintegration of the sugar-coated tablets.
[0008]
The present invention completed based on such findings is a sugar-coated tablet characterized in that the protective coating directly applied to the inner core tablet is composed of a water-soluble polymer and a water-soluble saccharide.
[0009]
DETAILED DESCRIPTION OF THE INVENTION
The protective film is a film directly applied to the inner core tablet between the inner core tablet and the sugar-coated film. In general, a water-soluble polymer such as hydroxypropylmethylcellulose is used. The action prevents the sugar-coating liquid from directly penetrating the inner core tablet during coating, and preventing moisture from penetrating into the tablet.After coating, the components in the inner core ooze into the sugar-coating layer, or the inner core tablet swells and the sugar coating is swollen. It is to prevent the layer from cracking. Usually, when this protective film is not applied, moisture permeation, oozing out of core tablet components, and cracking are likely to occur.
[0010]
Here, the inner core tablet is an uncoated tablet containing the main ingredient, which is also referred to as a plain tablet or a bare tablet.
[0011]
The water-soluble polymer of the present invention preferably has a low hygroscopic property and a low swelling property, and examples of the water-soluble polymer having such properties include hydroxypropylmethylcellulose and hydroxypropylcellulose. These may be blended singly or in combination of two or more.
[0012]
The water-soluble saccharides of the present invention are preferably saccharides having a solubility in water at 25 ° C. of 0.3 to 3 g / g. Examples of such saccharides include maltitol, erythritol, glucose and sucrose. Is mentioned. However, considering the penetration of moisture into the tablet during coating, it is desirable that the amount of water in the coating solution is small, so sucrose is particularly soluble in water and can be dissolved in a large amount even with a small amount of water. preferable.
The weight ratio of the water-soluble polymer to the water-soluble saccharide is 1: 0.1 to 1: 3. From the viewpoint of maintaining the film strength as the protective film, 1: 0.5 to 1: 1.5 is preferable.
The coating amount of the protective film comprising a water-soluble polymer and a water-soluble saccharide is usually 1 to 15% by weight with respect to the weight of the inner core tablet, although it depends on the formulation of the inner core tablet. From the point of prevention, 2 to 10% by weight is preferable.
[0013]
The sugar-coated tablet of the present invention can be prepared by forming an intermediate layer and an upper layer by an ordinary coating method, except that a protective film comprising a water-soluble polymer and a water-soluble saccharide is applied to the inner core tablet.
[0014]
【The invention's effect】
According to the present invention, it is possible to provide a sugar-coated tablet with a shortened disintegration time.
[0015]
【Example】
Hereinafter, the present invention will be described in more detail with reference to Examples, Comparative Examples, and Test Examples.
[0016]
Example 1
[Manufacture of inner core tablets]
Lactose 2700g
340 g of hydroxypropyl cellulose
Corn starch 1100g
Crystalline cellulose 340g
Low substituted hydroxypropylcellulose 200g
40g light silicic acid anhydride
Magnesium stearate 20g
The powder obtained by mixing the above components was tableted to obtain tablets with a tablet diameter of 9 mm and a tablet weight of 235 mg. This was used as an inner core tablet.
[0017]
[Manufacture of protective coating liquid]
After 50 g of hydroxypropylmethylcellulose was stirred and dissolved in 900 g of purified water, 50 g of sucrose was added and dissolved by heating at 40 ° C. to obtain a protective coating solution.
[0018]
[Manufacture of protective coating layer]
The inner core tablet was placed in a coating apparatus, and a protective coating solution was spray-coated, and a protective coating layer was applied to about 20 mg per tablet.
[0019]
[Manufacture of intermediate layer]
Pullulan 24g
Metroz SB-4 (manufactured by Shin-Etsu Chemical) 12g
Potato starch 24g
Pluronic F68 (Asahi Denka) 10.8g
Sucrose 1084.6g
Light anhydrous silicic acid 10.8g
Carmellose calcium 24g
Talc 208g
Calcium carbonate 208g
The above components were suspended in 535 g of purified water and dissolved by heating to prepare a coating solution. The coating solution was applied to tablets with the protective coating layer up to about 80 mg per tablet to form an intermediate layer.
[0020]
[Manufacture of top layer]
A coating solution was prepared by heating and dissolving 1000 g of sucrose in 490 g of purified water. The coating liquid was applied to the tablet applied up to the intermediate layer to about 50 mg per tablet to form an upper layer. Finally, glazing was performed with carnauba wax to obtain a sugar-coated tablet having a tablet weight of about 385 mg.
(Comparative Example 1)
[Manufacture of protective coating liquid]
100 g of hydroxypropylmethylcellulose was stirred and dissolved in 900 g of purified water to obtain a protective film solution.
[0021]
[Manufacture of protective coating layer]
The inner core tablet obtained in Example 1 was placed in a coating apparatus, sprayed with a protective coating solution, and a protective coating layer was applied to about 20 mg per tablet.
[0022]
[Manufacture of intermediate layer and upper layer]
The intermediate layer, the top layer and the polishing were carried out in the same manner as in Example 1 to obtain a sugar-coated tablet having a tablet weight of about 385 mg.
[0023]
(Example 2)
[Manufacture of inner core tablets]
Ibuprofen 1125g
Hydroxypropylcellulose 300g
Low substituted hydroxypropylcellulose 1425g
Crystalline cellulose 1500g
The powder obtained by mixing the above components was stirred and granulated using purified water as a granulating solvent, dried and then mixed with 21 g of Stemag. The obtained granules were tableted to obtain tablets with a tablet diameter of 9 mm and a tablet weight of 250 mg. This was used as an inner core tablet.
[0024]
[Manufacture of protective coating liquid]
After 50 g of hydroxypropylmethylcellulose was stirred and dissolved in 900 g of purified water, 50 g of sucrose was added and dissolved by heating at 40 ° C. to obtain a protective coating solution.
[0025]
[Manufacture of protective coating layer]
The inner core tablet obtained in Example 1 was placed in a coating apparatus, sprayed with a protective film solution, and a protective film layer was applied to about 20 mg per tablet.
[0026]
[Manufacture of intermediate layer and upper layer]
800 g of sucrose and 17 g of pullulan were dissolved by heating in 570 g of purified water to prepare a coating solution. A coating solution was applied to tablets with the protective coating layer up to about 85 mg per tablet to form a sugar coating layer. Finally, glazing was performed with carnauba wax to obtain a sugar-coated tablet having a tablet weight of about 355 mg.
(Test example)
For each of the 6 sugar-coated tablets obtained in Example 1 and Comparative Example 1, a disintegration test was conducted according to the 13th revised Japanese Pharmacopoeia using 37 ° C. purified water as a test solution. The results are shown in Table 1.
[0027]
[Table 1]
[0028]
According to Table 1, when the protective film made of hydroxypropylmethylcellulose and sucrose was applied (Example 1), the disintegration time was about 3 compared to the case where the protective film made only of hydroxypropylcellulose was applied (Comparative Example 1). It was found that it can be shortened.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP35061998A JP4465728B2 (en) | 1998-12-10 | 1998-12-10 | Dragees |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP35061998A JP4465728B2 (en) | 1998-12-10 | 1998-12-10 | Dragees |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000169365A JP2000169365A (en) | 2000-06-20 |
JP4465728B2 true JP4465728B2 (en) | 2010-05-19 |
Family
ID=18411706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP35061998A Expired - Fee Related JP4465728B2 (en) | 1998-12-10 | 1998-12-10 | Dragees |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4465728B2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4856323B2 (en) * | 2001-06-15 | 2012-01-18 | エスエス製薬株式会社 | Method for producing stable enteric-coated sugar-coated tablets |
JP4919605B2 (en) * | 2004-02-27 | 2012-04-18 | 大日本住友製薬株式会社 | Dragees |
JP5046202B2 (en) * | 2006-10-25 | 2012-10-10 | 浜田食品工業株式会社 | Dragees and methods for producing the same |
TWI455733B (en) | 2009-03-30 | 2014-10-11 | Toray Industries | A coating tablet collapsible in the oral cavity |
-
1998
- 1998-12-10 JP JP35061998A patent/JP4465728B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2000169365A (en) | 2000-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5232062B2 (en) | Chronotherapeutic dosage form | |
RU2428178C2 (en) | Sugar coatings and methods of their application | |
US9820982B2 (en) | Oxymorphone controlled release formulations | |
US5948440A (en) | Modified release matrix formulation of cefaclor and cephalexin | |
US20060193911A1 (en) | Controlled release venlafaxine formulations | |
US20090169587A1 (en) | Chronotherapeutic dosage forms | |
HU229152B1 (en) | Multiparticulate tablets with quick disintegration | |
US20030099710A1 (en) | Granule modulating hydrogel system | |
US20120034276A1 (en) | Solid preparation | |
JP6282676B2 (en) | Sustained release solid preparation with antiemetic action | |
JP2004533461A (en) | Swallow tablets containing paracetamol | |
JP4465728B2 (en) | Dragees | |
US20140065213A1 (en) | Sustained Release Paracetamol Formulations | |
DK2679216T3 (en) | Pharmaceutical form for modified release of betahistine | |
JP2005537295A (en) | Method for producing bicifazine | |
KR20010051807A (en) | Water-Based Film Coating Agents and Oral Solid Preparations | |
JP2002193792A (en) | Film-coated tablet and erosion preventing composition | |
JPH11116467A (en) | Sugar-coated tablet | |
JP4759905B2 (en) | Dragees | |
TW202033221A (en) | Film coating composition and solid preparation | |
US11701350B2 (en) | Dextromethorphan extended release pharmaceutical composition | |
JP2021518424A (en) | Oral tablet composition of various doses of lenalidomide | |
US20040228918A1 (en) | Granule modulating hydrogel system | |
TW201609197A (en) | Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration | |
ZA200301851B (en) | Sustained release formulations of oxymorphone. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051102 |
|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090605 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090623 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090820 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091104 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091218 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100202 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100215 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130305 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130305 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130305 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140305 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |